Skip to main content
Equibles
VIVS logo

VIVS · VivoSim Labs, INC. · Metrics

Track VIVS — free

Use VIVS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VIVS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.21 +0.01 (+6.26%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Management has performed an analysis and concluded that substantial doubt exists about our ability to continue as a going concern. Separately, our independent registered public accounting firm included in its opinion for the year ended March 31, 2026 an explanatory paragraph referring to our recurring losses from operations and expressing substantial doubt in our ability to continue as a going concern without additional capital becoming available.”
View the 10-Q filed Aug 12, 2026
Market Cap
$3.33M
Shares
14.85M
Volume · Oct 5 403.67K Avg daily vol (3M) 5.82M

VIVS metrics

33 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.20
Market cap
$3.33M

Price action

20 metrics
Price change (1W)
-12.3%
Price change (30D)
-30.3%
Price change (3M)
-80.0%
Price change (6M)
-88.4%
Price change (YTD)
-89.1%
Price change (1Y)
-94.3%
Trailing year
Price change (5Y)
—
52-week high
$3.46
52-week low
$0.20
Change from 52-week high
-94.3%
Change from 52-week low
+0.0%
Annualized volatility
125.6%
Annualized volatility (3M)
142.6%
Beta
1.3
RSI (14D)
27.9
Price vs SMA 50
-33.4%
Price vs SMA 200
-84.3%
Avg volume (3M)
5.82M
Relative volume
0.1
Average dollar volume
$3.27M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
14.85M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
—
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
—
Debt / equity
—
Current ratio
—
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
—
Total assets
—
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
25
13F filer change QoQ
+1
Institutional ownership
0.7%

Short interest

3 metrics
Short interest
3.8%
Latest settlement · 1.1 days to cover
Days to cover
1.1d
Short-squeeze score
38 / 100

Insider activity

2 metrics
Net insider buying (90D)
$2,804
Insider-sentiment score
77 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1497253 CUSIP 68620A302 Visit website Investor relations